Objective: To assess the effect of injectable hormone PL group but did not change in the E and E+P patients.
Introduction
plasma renin activity (PRA), plasma aldosterone, During the menopause, low plasma oestrogen levels and causes sodium retention. These factors increase are associated with an increased risk of cardiovascuboth extracellular volume and cardiac output. 9 Furlar disease. [1] [2] [3] [4] Hormone replacement therapy (HRT) thermore, oestrogen treatment induces vasomay modify this risk factor, although this effect is dilation. 10 Hypertensive patients may also have still a matter of debate. 5 It is possible that ethnic and insulin resistance, with increased plasma glucose environmental factors including lifestyle may interand insulin levels. 11, 12 act to explain variation in risk for hypertension in The interaction of hypertension with these other menopausal women from differing populations. We risk factors must be considered for the assessment have recently reported that in our population the of HRT in menopausal women, including overfrequency of hypertension and obesity increased at weight and blood lipid levels. 13 Plasma fibrinogen the time of menopause. 6 This phenomenon seems to has also been proposed as an independent risk factor vary in different ethnic roups, as the Framingham for cardiovascular disease. 14 In this study we report study did not report changes in blood pressure (BP), the results of a randomised double-blind trial, exambody weight or blood glucose. 7 By contrast, ining the effects of injectable HRT in menopausal increased rates of hypertension during the menowomen with mild to moderate hypertension. pause, have been reported in the People's Republic of China. 
Materials and methods
The effects of HRT on cardiovascular risk factors including hypertension are not completely underWe carried out a prospective randomised doublestood because of the interaction of several other facblind study to assess the effect of injectable HRT tors. Sex steroids have a complex interaction with (oestrogen, and oestrogen prasterone preparations, vs a placebo). Fifty-five women were selected according to the following criteria: menopausal, and without evidence of cardiovascular or uterine cose and urea levels were measured by an enzymatic colorimetric test, and serum creatinine by the Jaffe disease. The menopause was defined when amenorrhea for more than one year in women aged more method. Hormones were measured by radioimmunoassay than 40 years with previous regular menses. Mild The purpose of the study and its possible risks were was measured by radioimmunoassay in solid phase based in mono and policlonal 125 I antibodies. Intraexplained to the patients, and all 55 accepted inclusion. Twenty-three patients who were taking assay variation coefficients were 2.8% to 5.5% for FSH, 13.1% to 13.4% for insulin, 8.9% to 18.3% for antihypertensive drugs stopped therapy as requested (four of them on diuretics were randomly aldosterone, and 4.2% to 8.3% for PRA. Insulin was measured with a kit from Diagnostic Product Corassigned, one to the placebo (PL), one to the estradiol (E), and two to the estradiol plus prasterone poration. Fibrinogen was measured with a kit from Baxter Diagnostics (Deerfield, IL, USA), using a (E+P) groups). After 15 days washout period, five patients had a DBP over 105 mm Hg, so they were fibrinometer. excluded from the study and restarted treatment immediately.
Ethical considerations
The remaining 50 patients were randomly allocated to three groups for treatment with intramuscu-
The local ethical committee approved the research protocol, requiring close surveillance and strict lar injections given every month for three consecutive months: Group 1: 16 patients were given PL exclusion criteria. Patients were to be excluded if DBP exceeded 105 mm Hg on a single recording. All (saline solution), seven of whom had been on antihypertensive therapy. Group 2: 16 patients receiving patients signed informed consent forms. The pharmaceutical company marketing the hormonal prep-10 mg estradiol valerianate (E), seven of them previously on antihypertensive therapy. Group three:
arations was unaware of the study. 18 patients on estradiol valerianate 4 mg plus prasterone enantate 200 mg (E+P). Nine of them had preStatistical analysis viously stopped antihypertensive medication.
The patients were not aware of the type of treatDifferences between the three groups at each point of observation were tested by analysis of variance ment nor the characteristics of the substance injected. No specific diet nor dietary instructions (ANOVA). Significance between pairs of groups and the differences in changes from baseline values were given to the patients, and they were followed for five visits at 30, 45, 60, 75 and 90 days of treatbetween the treatment and the placebo group were evaluated in post-hoc analysis by the Least Signifiment. Discontinuation from the trial planned for persistent endometrial bleeding, increase in DBP to cant Difference test. For each group of treatment the initial and final values were compared by Student's above 105 mm Hg, or intercurrent disease occurring during the study. An investigator, blind to the treatt-test for dependent samples. Regression analysis was used to examine the relationships between ment assignment, made the data collection.
At the initial visit we obtained details of smoking PRA, plasma aldosterone and insulin and the changes in BP. Adjustments were made with covarihabit, alcohol intake, occupation, physical activity, and parity. At the initial, and all subsequent visits, ance analysis for the following factors: PRA, aldosterone, FSH, cholesterol and its fractions HDL and we also measured standing height, weight (body mass index [BMI] kg/m 2 was calculated), arterial BP LDL and insulin. In view of the multiple comparisons made, significance was accepted with P Ͻ 0.01. and thorax/hip, waist/hip and abdomen/hip circumference ratios. Standing and recumbent arterial BP was taken as the mean of three measurements at the Results start, the middle, and at the end of each interview after a minimum of 5 min rest, using a mercury
No patient missed any follow-up visit in which no more than 3 days delay was permitted. After 1 sphygmomanometer with a proper cuff placed on the dominant arm. Phases I and V of the Korotkoff month of treatment, three out of the 50 patients abandoned the study for personal reasons unrelated sounds were used to determine systolic and diastolic BP. At initiation and at the end of treatment, a to treatment (one from the E group and two from the E+P group). Three patients were excluded because fasting blood sample was taken to measure blood levels of glucose, cholesterol, LDL-cholesterol, HDLof increased BP (one from the PL group, and two from the E+P group). Our analysis includes all cholesterol, PRA, aldosterone and insulin. Creatinine clearance rate was calculated with the formula patients followed at each scheduled time point. Table 1 shows the characteristics of the patients observed. Comparing the BP values among the three groups, no difference was found at randomisation or in the three treatment groups. The women were predominantly obese, multiparous, with mean ages 55.1 at any time during the observation. At the end of treatment, comparisons of standing and recumbent to 58.6 years. Thirty-eight of them were housewives. Only five patients reported that they were smokers, SBP and DBP were not significantly different. The analysis of hormone changes during treatand three had moderate to occasional alcohol consumption. No change was observed between the ment, showed a significant decrease of PRA, aldosterone and insulin in the patients receiving E or E+P serum levels of cholesterol or LDL-cholesterol before and during the trial in the three groups of treatment ( Figure 4) . PRA fell in all groups, but by a larger amount in the hormone treated groups. In the E+P (Figure 1) . FSH was lower in the groups with oestrogen and oestrogen-prasterone treatment.
group, the decrease was from 14.3 to 2.2 ng/ml. Using analysis of covariance (ANCOVA) the Figures 2 and 3 show systolic and diastolic BP obtained during the study. Surprisingly in the PL adjusted means values were 10.8 and 2.00 respectively (P Ͻ 0.01) a P Ͻ 0.010. In the E group the group, values at the end of the study were lower, as compared to those taken at randomisation, both for adjusted means were 11.5 and 3.5 before and after treatment (P Ͻ 0.018). The differences for the PL standing and recumbent BP. Change for SBP was −13.1 (t = 3.93, P = 0.002) for standing and 16.2 group were not significant. The reduction in plasma aldosterone in the E group was significant but when (t = 5.39, P Ͻ 0.001) for recumbent measurements. Changes in recumbent DBP in the placebo group was ANCOVA was applied, this significance was lost. The change in plasma aldosterone in the E+P group −9.0 (t = 4.29, P Ͻ 0.001) for standing, but this trend was not statistically significant. In the treated was highly significant, decreasing from 98 to 53 pg/ml. When the means were adjusted by groups, no changes in systolic or diastolic BP were ANCOVA the values were 102.6 and 49. 4 al, 21 and Barret-Connor et al 22 found that women receiving oestrogen therapy had lower BP levels (P Ͻ 0.003). Plasma insulin levels decreased significantly in all three groups, although a more sigthan controls. By contrast, Markovitz et al 23 in a cross-sectional study found that menopausal women nificant change was found for the hormone treated groups. The diminution in the E+P group, was from taking HRT had higher BP levels. Wren 24 in a review of more than 100 published papers concluded that 18.3 to 7.6 U/ml. When the ANCOVA was applied for the insulin values, the difference in the placebo oestrogens reduce the cardiovascular risk factors. Lip et al 25 in an open prospective study of women group was no longer significant, but it persisted in the two treatment groups (P Ͻ 0.002 for the E group who required HRT for amelioration of menopausal symptoms, found no changes in SBP or DBP over 14 and P Ͻ 0.0001 for the E+P group). The creatinine clearance rates remained unchanged in all three months of follow-up. In view of the increased frequency of hypertension in menopausal women groups.
found in several populations, we explored the HRT effect in women with mild to moderate hyperten-
Discussion
sion for a limited period of time. Antihypertensive medication was withdrawn to avoid the possible The effects of oestrogen on systemic BP are controversial. 17 Oral contraceptives may induce a marginal interaction of medication which may confuse results. One problem is that the number of patients increase in BP although contraceptive medication contains higher doses than preparations of HRT for in the trial was small, and therefore we may have had insufficient power to detect differences between menopausal women. 18 It has been suggested that HRT does not have any effect on BP in normotensive the three treatment arms; this effect may explain the lack of effect of therapy on variables that are known women 19 and information from epidemiological studies suggests that oestrogen replacement therapy to be strongly influenced by hormone therapy. Two weeks of wash-out may be too short an interval to may in fact have the opposite effect. Weiss et al 20 suggest furthermore that oestrogen may protect reverse the effects of the antihypertensive therapy, although this interval was the same manner as in against the development of hypertension. Lind et other studies. [26] [27] [28] The exclusion criteria for patients ings, may be due to the withdrawal of antihypertensive therapy with a decrease in activity of the reninwho developed a DBP higher than 105 mm Hg was necessary to protect the patients' safety, but this may angiotensin system, as most antihypertensive drugs increase renin levels. HRT seems therefore to be a source of bias for the analysis of BP, and other variables. enhance this reduction. This is important in view of the opposing effect of larger oestrogen doses in oral We found that untreated patients showed a progressive decline in BP during follow-up. We intercontraceptive therapy, which increases angiotensinogen synthesis. [29] [30] [31] [32] [33] PRA increases in parallel with pret this finding by two factors: firstly a bias caused by the exclusion (for ethical reasons) of patients who plasma estradiol levels during pregnancy. 34 There were no significant changes observed in the insulin sustained a marked rise in BP after 2 weeks of discontinuing antihypertensive treatment, and secvalues or change in insulin levels between the PL and the two HRT groups. Fasting plasma insulin levondly a placebo effect, on follow-up of mild to moderately hypertensive subjects with the patients els decreased in all three groups, but blood glucose remained unchanged. We interpret this finding to becoming accustomed to participating in the study, or because they developed increased motivation to mean that the withdrawal of antihypertensive therapy causes a reduction of peripheral resistance to comply with the general recommendations on lifestyle. The fall in BP was less in women who insulin. Antihypertensive treatment with thiazides and beta-blockers may increase insulin resistreceived either of the two HRT regimes compared with placebo strongly suggests that HRT may have ance. 35, 36 Our results show a recovery of insulin sensitivity after withdrawal of antihypertensives and some pressor effects that did not become fully apparent in the limited 90-day duration of the study.
that HRT enhances this recovery. Further studies should examine the effects of HRT on insulin sensiThe fall in PRA and aldosterone levels during the study parallelled the decrease of systemic BP. This tivity in patients receiving antihypertensive drugs. Fibrinogen, a recently recognized independent prewas more significant in patients receiving active HRT, and is more evident when we examined the dictor for coronary heart disease, has been found to fall after oestrogen taken alone or in combination change in PRA values between the PL and active HRT groups; the change was significant when we with a progestin in menopausal women. 4 In the present study fibrinogen remained unchanged in compared the PL and the E+P groups. These find- had a slight influence on these changes.
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